文献速递肿瘤 PET/CT

子宫内膜腺癌无全身治疗出现眼影征的18F-FDG PET/CT罕见影像陷阱

The Eye-Black Sign on 18F-FDG PET/CT in Endometrial Adenocarcinoma Without Prior Systemic Therapy: A Rare Imaging Pitfall.
PubMed 文献 · Clin Nucl Med · 2026-06-04

本文报道一例53岁子宫内膜腺癌患者,经手术及辅助阴道近距离放疗后18个月随访PET/CT显示双侧下眼睑对称性FDG摄取(SUVmax 9.7),无肿瘤复发,活检示慢性炎症。眼影征此前主要见于接受全身抗肿瘤治疗者,本病例提示该良性影像陷阱也可发生于无全身治疗患者。

要点

  • 眼影征表现为双侧下眼睑对称性FDG摄取,可为良性炎症,避免误判为转移。
  • 该征象并非仅见于接受全身抗肿瘤治疗的患者。
  • 对可疑眼睑摄取应结合病史,必要时活检以排除病理过程。

核心结论

  • 眼影征可在无全身抗肿瘤治疗的子宫内膜腺癌患者中出现,应识别为良性影像陷阱。

研究设计与样本

  • 单例病例报告:53岁子宫内膜腺癌女性,术后接受辅助阴道近距离放疗,未行全身治疗,18个月后随访行18F-FDG PET/CT。

主要发现

  • 随访PET/CT显示双侧下眼睑FDG摄取,SUVmax为9.7,无肿瘤复发。
  • 眼睑病灶活检显示慢性炎症改变。

临床怎么用

  • 阅片遇双侧下眼睑对称性FDG摄取时,应想到眼影征这一良性陷阱,结合临床及必要时活检避免误诊。

局限性

  • 单例病例报告,证据级别有限,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Incidental findings on 18F-FDG PET/CT may mimic pathologic processes, making recognition of imaging pitfalls essential. The eye-black sign, a rare finding characterized by bilateral symmetric FDG uptake in the lower eyelids, has mainly been reported in patients receiving systemic oncologic therapy. We present a 53-year-old woman with endometrial adenocarcinoma treated surgically and with adjuvant vaginal brachytherapy, without systemic therapy. Follow-up PET/CT 18 months later showed bilateral lower eyelid uptake (SUVmax: 9.7) without recurrence. Biopsy revealed chronic inflammatory changes. This case demonstrates that the eye-black sign can occur without systemic therapy and should be recognized as a benign imaging pitfall.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Güzel F, Nacir M, Çetin A, et al. The Eye-Black Sign on 18F-FDG PET/CT in Endometrial Adenocarcinoma Without Prior Systemic Therapy: A Rare Imaging Pitfall. Clin Nucl Med. 2026. PMID: 42257566. doi:10.1097/RLU.0000000000006566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。